Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AV7909 Full Dose (0.5 mL)
AV7909 Full Dose · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Full Dose Schedule 1 | EXPERIMENTAL | This study group will receive full dose AV7909 (0.5mL) at study days 1, 15, 181 and 366. A placebo full dose (0.5 mL) will be administered between the second and third dose of AV7909 at study day 29. Update: Enrollment to this treatment arm was closed on 13 May 2024. |
| Full Dose Schedule 2 | EXPERIMENTAL | This study group will receive of AV7909 full dose (0.5 mL) at study days 1, 29, 181 and 366. A placebo full dose (0.5 mL) will be administered between the first and second dose of AV7909 at study day 15. Update: Enrollment to this treatment arm was closed on 13 May 2024. |
| Half Dose Schedule 1 | EXPERIMENTAL | This study group will receive of AV7909 half dose (0.25 mL) at study days 1, 15, 181 and 366. A placebo half dose (0.25 mL) will be administered between the second and third dose of AV7909 at study day 29. |
| Half Dose Schedule 2 | EXPERIMENTAL | This study group will receive of AV7909 half dose (0.25 mL) at study days 1, 29, 181 and 366. A placebo full dose (0.25 mL) will be administered between the first and second dose of AV7909 at study day 15. |
| Name | Type | Description |
|---|---|---|
| AV7909 Full Dose (0.5 mL) | BIOLOGICAL | AV7909 Anthrax Vaccine is being developed by Emergent Product Development Gaithersburg Inc. (Emergent) for post-exposure prophylaxis (PEP) of disease in persons 18 through 65 years of age following suspected or confirmed B. anthracis exposure when administered in conjunction with the recommended antibacterial regimen. AV7909 is a combination product containing BioThrax and CPG 7909, a synthetic immunostimulatory oligodeoxynucleotide that has been shown to be a potent vaccine adjuvant. CPG 7909 is a Toll-like receptor 9 agonist designed to induce both an enhanced antigen-specific antibody response and a natural killer T-cell immune response when used in combination with prophylactic (preventative) or therapeutic vaccines. |
| AV7909 Half Dose (0.25 mL) | BIOLOGICAL | AV7909 Anthrax Vaccine is being developed by Emergent Product Development Gaithersburg Inc. (Emergent) for PEP of disease in persons 18 through 65 years of age following suspected or confirmed B. anthracis exposure when administered in conjunction with the recommended antibacterial regimen. AV7909 is a combination product containing BioThrax and CPG 7909, a synthetic immunostimulatory oligodeoxynucleotide that has been shown to be a potent vaccine adjuvant. CPG 7909 is a Toll-like receptor 9 agonist designed to induce both an enhanced antigen-specific antibody response and a natural killer T-cell immune response when used in combination with prophylactic (preventative) or therapeutic vaccines. |
| Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL) | BIOLOGICAL | Sodium chloride 9 mg water for injection Quantum satis (q.s.). It contains no bacteriostat, antimicrobial agent, or added buffer. The solution may contain hydrochloric acid and/or sodium hydroxide for pH adjustment (pH 4.5-7.0). |
| Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL) | BIOLOGICAL | Sodium chloride 9 mg water for injection Quantum satis (q.s.). It contains no bacteriostat, antimicrobial agent, or added buffer. The solution may contain hydrochloric acid and/or sodium hydroxide for pH adjustment (pH 4.5-7.0). |
Inclusion Criteria: 1. Male or non-pregnant females, 18 through 65 years of age, inclusive. 2. Willing and able to provide written informed consent prior to initiation of study procedures. 3. In relatively stable health, as determined by medical history and physical examination. Any chronic medical...
AV7909 Full Dose is an investigational monoclonal antibody being studied for use in anthrax. It is currently in Phase 2 clinical development as a potential preventive or therapeutic agent against anthrax infection.
AV7909 Full Dose targets TLR9, a toll-like receptor involved in immune system activation. By engaging TLR9, the monoclonal antibody is designed to modulate immune responses relevant to anthrax.
AV7909 Full Dose is being developed by Icon Plc, a biopharmaceutical company listed on the stock exchange under the ticker symbol ICLR.
AV7909 Full Dose is currently in Phase 2 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities for commercial use.
AV7909 Full Dose is being evaluated in one active clinical trial, NCT05997264, titled 'Anthrax AV7909 Boost Evaluation Study.' This Phase 2 trial is enrolling 220 healthy volunteers in the United States and is currently active but not recruiting participants.
Yes, AV7909 Full Dose is also known as AV7909 Full Dose (0.5 mL). The alternative name refers to the specific volume of the dose being administered in clinical studies.